Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants
Public ClinicalTrials.gov record NCT05166421. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1, Randomized, Open Label, Three-arm, Single Dose, Parallel Group Study to Compare AZD7442 (AZD8895 + AZD1061) Pharmacokinetic Exposure Following Intramuscular Administration as a Co-formulation Versus Administration From Two Separate Vials of the Individual Monoclonal Antibodies in Adult Healthy Participants
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study will assess pharmacokinetic (PK) comparability between different formulations of AZD7442, which is a combination of two individual monoclonal antibodies (mAbs), AZD8895 and AZD1061.
Study identification
- NCT ID
- NCT05166421
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 224 participants
Conditions and interventions
Conditions
Interventions
- AZD7442 Biological
- AZD8895 (clonal cell line material) Biological
- AZD1061 (clonal cell line material) Biological
- AZD8895 (cell pool material) Biological
- AZD1061 (cell pool material) Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 29, 2021
- Primary completion
- Jul 18, 2023
- Completion
- Jul 18, 2023
- Last update posted
- Nov 24, 2024
2021 – 2023
United States locations
- U.S. sites
- 14
- U.S. states
- 8
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Anniston | Alabama | 36207 | — |
| Research Site | Cullman | Alabama | 35055 | — |
| Research Site | Scottsdale | Arizona | 85260 | — |
| Research Site | Chula Vista | California | 91911 | — |
| Research Site | La Mesa | California | 91942 | — |
| Research Site | Long Beach | California | 90806 | — |
| Research Site | North Hollywood | California | 91606 | — |
| Research Site | Edgewater | Florida | 32132 | — |
| Research Site | Lake Worth | Florida | 33462 | — |
| Research Site | Orlando | Florida | 320919 | — |
| Research Site | Meridian | Idaho | 83642 | — |
| Research Site | Berlin | New Jersey | 08009 | — |
| Research Site | Union | South Carolina | 29379 | — |
| Research Site | Houston | Texas | 77058 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05166421, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 24, 2024 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05166421 live on ClinicalTrials.gov.